Antipsychotic dose-sparing effect with addition of memantine

Annals of Pharmacotherapy

Volumn 39, Issue 9, 2005, Pages 1573-1576

  Sleeper, Rebecca B ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Alzheimer's disease; Antipsychotic; Memantine

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; DOXAZOSIN; MEMANTINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OMEPRAZOLE; PARACETAMOL; RISPERIDONE; RIVASTIGMINE; VALPROATE SEMISODIUM;

ADJUVANT THERAPY; AGED; AGGRESSION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; COGNITION; DRUG DOSE REDUCTION; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGGRESSION; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MEMANTINE; RISPERIDONE;

EID: 23944467492     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G207     Document Type: Article

References (10)

1. FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. www.fda.gov/cder/drug/advisory/ antipsychotics.htm (accessed 2005 Apr 11).
2. Anand R, Koumaras B, Hartman R. The effects of rivastigmine on behavioral symptoms in severe AD patients in a nursing home setting (abstract). Neurobiol Aging 2000:21(suppl 1):5220.
3. Gardener ME, Ditmanson LF, Garret RW, Slack M. Effectiveness of divalproex sodium in severe dementia related aggression. Consult Pharm 2001;16:839-43.
4. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000;20:195-203.
5. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
6. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewitt L, et al. Guidelines for managing Alzheimer's disease: part JJ. Treatment. Am Fam Physician 2002;65:2525-34.
7. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
8. Spiegel R, Brunner C, Ermini-Funfschilling D, Monsch A, Notter M, Puxty J, et al. A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients). J Am Geriatr Soc 1991;39:339-47.
9. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild-moderate vascular dementia: a randomized, placebo controlled trial (MMM 300). Stroke 2002;33:1834-9.
10. Tariot PN. Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.